{"entity":{"id":"nct07052253","kind":"trial","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","aka":[],"tldr":"A phase 2 trial of Tinengotinib, Cadonilimab, Ivonescimab in hepatocellular carcinoma, run by Akeso, now recruiting.","summary":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. is a phase 2 interventional study registered as NCT07052253 by Akeso, with 100 participants planned, started 2025-07-18 and due to reach its primary completion in 2027-05-10. Interventions recorded: TT-00420 (tinengotinib), AK104, AK112. Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07052253","url":"https://clinicaltrials.gov/study/NCT07052253"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc","hcc-advanced"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["tinengotinib","cadonilimab","ivonescimab"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07052253","phase":"2","setting":"An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet in Patients With Advanced Hepatocellular Carcinoma.","sponsor":"Akeso","started":"2025-07-18","startedType":"actual","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07052253/","neighbours":{"cancer":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}